Vibe Bio events
Webinar on-demand
Biopharma BD meets AI
Watch this insightful webinar with Alok Tayi, PhD, Co-Founder and CEO of Vibe Bio, on how AI is accelerating the business development process, helping executive teams move faster by making it easier to collect, manage, access, and evaluate drug assets, thus empowering them to conduct more thorough due diligence with the same resources.
Webinar on-demand
Bottlenecks to breakthroughs: How AI is reshaping biopharma BD&L
Biopharma BD&L and search & evaluation teams are the front lines to identifying and advancing new assets and platforms that shape a company’’’s pipeline. Their work is diverse: from competitive benchmarking and program assessment to commercial forecasting, all while tracking the explosion of global pharmaceutical innovation.
Webinar on-demand
Unlock smarter drug development decisions with AI
Watch this webinar with Alok Tayi, Founder and CEO at Vibe Bio, and Andy Birch, Director of Product at Vibe Bio, to learn how AI-driven pipeline analysis platforms can make for faster, more accurate drug development decisions—while still leveraging your team’s expertise.
Additional resources
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches.
Orphan Therapeutics Accelerator Announces Foundational Partnerships
The Orphan Therapeutics Accelerator, a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
Pharma portfolio analytics in a gen AI world
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Navigating pharma strategy and portfolio prioritization: A Q&A
With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.
Lessons from a pioneer in pharmaceutical decision-making
Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches.
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
Pharma portfolio analytics in a gen AI world
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Impact Review – Founding Vibe Bio
The Impact Review article explores Alok Tayi’s personal experience with rare disease drove him towards a mission – to fund cures for rare diseases.
STAT – Upending drug industry financing
This article looks at how Vibe Bio CEO, Alok Tayi, is seeking to upend drug industry financing.
Forbes – Alok Tayi’s new start-up is putting drug development into patients’ hands
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.
Endpoint News – Parents become drug developers to save their children’s lives
Endpoint News addressed how parents of children with rare disease are challenging the status quo in drug development.
Coindesk – How Vibe Bio plans to retool biotech funding
In this article, Vibe Bio founder and CEO, Alok Tayi, explains how a decentralized science approach can retool biotech funding.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
Revolutionizing Drug Development for Rare Diseases Through AI | Alok Tayi
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases…
Mother-Son Duo Offer Biopharma KOL Mapping with Adnexi CEO Sandra Shpilberg
Sandra Shpilberg, Co-founder and CEO of Adnexi, discusses using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”
Orphan Therapeutics Accelerator Announces Foundational Partnerships
The Orphan Therapeutics Accelerator, a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.